5 drug(s) with this reaction
3,193 total reports
Chronic Kidney Disease has been reported as an adverse reaction across 5 drug(s) manufactured by Abbvie Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 3,193 adverse event reports mention chronic kidney disease in connection with Abbvie Inc products.
This page provides a breakdown of which Abbvie Inc drugs are most commonly associated with chronic kidney disease, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Abbvie Inc drugs have chronic kidney disease listed in their FDA adverse event reports, sorted by report count:
In addition to chronic kidney disease, the following adverse reactions have been reported across Abbvie Inc's drug portfolio:
5 drug(s) manufactured by Abbvie Inc have chronic kidney disease listed in their FDA adverse event reports: FENOFIBRATE, RITONAVIR, LOPINAVIR AND RITONAVIR, PARICALCITOL, PANCRELIPASE.
There are a combined 3,193 reports of chronic kidney disease across 5 Abbvie Inc drug(s) in the FDA adverse event database.